Forward catalyst · IMNN

niraparib

Sponsor IMNN · listed as IMNN

READOUT Phase 2;Phase 3 Confidence: medium Source: clinicaltrials

niraparib is a clinical-stage drug asset sponsored by IMNN, listed as IMNN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jun 2027 (month precision, medium confidence), tied to trial NCT03651206. The asset is in Phase 2;Phase 3 and currently recruiting, studied in Ovarian Carcinosarcoma. It appears across 11 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-06-30

As disclosedJun 2027

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT03651206

PhasePHASE2;PHASE3

StatusRECRUITING

Lead sponsorARCAGY/ GINECO GROUP

Listed asIMNN

Condition(s)Ovarian Carcinosarcoma; Endometrial Carcinosarcoma

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More IMNN catalysts